Beigene
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry. The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
DitchCarbon Score
How does Beigene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beigene's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beigene's reported carbon emissions
In 2024, BeiGene reported total carbon emissions of approximately 755,827,000 kg CO2e. This figure includes Scope 1 emissions of about 3,547,000 kg CO2e, primarily from mobile and stationary combustion, and Scope 2 emissions of approximately 89,591,000 kg CO2e, mainly from purchased electricity. The majority of their emissions, around 662,688,000 kg CO2e, fall under Scope 3, which encompasses various categories such as purchased goods and services (about 505,006,000 kg CO2e) and business travel (approximately 17,628,000 kg CO2e). In comparison, their 2023 emissions were reported at about 555,892,000 kg CO2e, with Scope 1 at 2,462,000 kg CO2e and Scope 2 at approximately 76,465,000 kg CO2e. This indicates a significant increase in emissions from 2023 to 2024. BeiGene has set ambitious climate commitments, aiming to reduce both Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, they target a 30% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2020 baseline. They also plan to reduce their Scope 1 and 2 emissions by 25% per unit of internally manufactured commercial products by 2026, using 2021 as a baseline. These commitments reflect BeiGene's proactive approach to addressing climate change and reducing their carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 535,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,929,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Beigene is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
